Activation of Astroglial Connexin is Involved in Concentration-Dependent Double-Edged Sword Clinical Action of Clozapine

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Feb 15

PMID 32054069

Citations 20

Authors

Kouji Fukuyama

Ruri Okubo

Masahiko Murata

Takashi Shiroyama

Motohiro Okada

Affiliations

Soon will be listed here.

Abstract

Clozapine (CLZ) is a gold-standard antipsychotic against treatment-refractory schizophrenia, but is one of the most toxic antipsychotic agents. Pharmacological mechanisms of the double-edged sword clinical action of CLZ remain to be clarified. To explore the mechanisms of CLZ, the present study determined the astroglial transmission associated with connexin43 (Cx43), which is the most principal expression in astrocytes and myocardial cells, and expression of Cx43 in primary cultured astrocytes. Both acute and subchronic administrations of CLZ concentration-dependently increased Cx43-associated astroglial release of l-glutamate and d-serine, whereas therapeutic-relevant concentration of CLZ acutely did not affect but subchronically increased astroglial release. In contrast, after the subchronic administration of therapeutic-relevant concentration of valproate (VPA), acute administration of therapeutic-relevant concentration of CLZ drastically increased Cx43-associated astroglial releases. VPA increased Cx43 expression in cytosol fraction without affecting plasma membrane fraction, whereas CLZ increased Cx43 expression in both fractions. Acute administration of therapeutic-relevant concentration of CLZ drastically increased Cx43 expression in the plasma membrane fraction of astrocytes subchronically treated with VPA. The present findings suggest that CLZ-induced the activation of Cx43-associated channel activity and transported Cx43 to plasma membrane, probably contribute to the double-edged sword clinical action of CLZ, such as improvement of cognitive dysfunction and CLZ-induced myocarditis.

Citing Articles

Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.

Okubo R, Okada M, Motomura E Biomolecules. 2024; 14(9).

PMID: 39334894 PMC: 11430065. DOI: 10.3390/biom14091128.

A Novel Gliotransmitter, L-β-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine.

Fukuyama K, Motomura E, Okada M Biomolecules. 2023; 13(9).

PMID: 37759688 PMC: 10526296. DOI: 10.3390/biom13091288.

Connexin 43 Phosphorylation: Implications in Multiple Diseases.

Zhang M, Wang Z, Chen N Molecules. 2023; 28(13).

PMID: 37446576 PMC: 10343229. DOI: 10.3390/molecules28134914.

The Effects of Antipsychotics in Experimental Models of Krabbe Disease.

Sharma K, Dev K Biomedicines. 2023; 11(5).

PMID: 37238985 PMC: 10215783. DOI: 10.3390/biomedicines11051313.

Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine.

Fukuyama K, Motomura E, Okada M Biomolecules. 2023; 13(5).

PMID: 37238731 PMC: 10216842. DOI: 10.3390/biom13050862.

References

Fukuyama K, Okada M . Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites. Br J Pharmacol. 2018; 175(22):4253-4265. PMC: 6193875. DOI: 10.1111/bph.14491. View

Fukuyama K, Kato R, Murata M, Shiroyama T, Okada M . Clozapine Normalizes a Glutamatergic Transmission Abnormality Induced by an Impaired NMDA Receptor in the Thalamocortical Pathway via the Activation of a Group III Metabotropic Glutamate Receptor. Biomolecules. 2019; 9(6). PMC: 6628267. DOI: 10.3390/biom9060234. View

Dallerac G, Rouach N . Astrocytes as new targets to improve cognitive functions. Prog Neurobiol. 2016; 144:48-67. DOI: 10.1016/j.pneurobio.2016.01.003. View

Okada M, Fukuyama K, Kawano Y, Shiroyama T, Ueda Y . Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>. Pharmacol Res Perspect. 2019; 7(1):e00457. PMC: 6323135. DOI: 10.1002/prp2.457. View

Nakano T, Hasegawa T, Suzuki D, Motomura E, Okada M . Amantadine Combines Astroglial System Xc Activation with Glutamate/NMDA Receptor Inhibition. Biomolecules. 2019; 9(5). PMC: 6572554. DOI: 10.3390/biom9050191. View

Xiang Y, Zhang Z, Weng Y, Zhai Y, Li W, Cai Z . Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res. 2006; 83(2-3):201-10. DOI: 10.1016/j.schres.2006.01.011. View

Okada M, Fukuyama K, Shiroyama T, Ueda Y . Carbamazepine Attenuates Astroglial L-Glutamate Release Induced by Pro-Inflammatory Cytokines via Chronically Activation of Adenosine A Receptor. Int J Mol Sci. 2019; 20(15). PMC: 6695599. DOI: 10.3390/ijms20153727. View

Dambach H, Hinkerohe D, Prochnow N, Stienen M, Moinfar Z, Haase C . Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. Epilepsia. 2013; 55(1):184-92. DOI: 10.1111/epi.12473. View

Varma S, Bishara D, Besag F, Taylor D . Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2013; 1(2):47-66. PMC: 3736902. DOI: 10.1177/2045125311405566. View

10.

de la Fuente Revenga M, Ibi D, Cuddy T, Toneatti R, Kurita M, Ijaz M . Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity. Neuropsychopharmacology. 2018; 44(2):443-454. PMC: 6300555. DOI: 10.1038/s41386-018-0143-4. View

11.

Mylvaganam S, Ramani M, Krawczyk M, Carlen P . Roles of gap junctions, connexins, and pannexins in epilepsy. Front Physiol. 2014; 5:172. PMC: 4019879. DOI: 10.3389/fphys.2014.00172. View

12.

Mitterauer B . Loss of function of glial gap junctions may cause severe cognitive impairments in schizophrenia. Med Hypotheses. 2009; 73(3):393-7. DOI: 10.1016/j.mehy.2009.04.003. View

13.

Javitt D . Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007; 78:69-108. DOI: 10.1016/S0074-7742(06)78003-5. View

14.

Krystal J, DSouza D, Mathalon D, Perry E, Belger A, Hoffman R . NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003; 169(3-4):215-33. DOI: 10.1007/s00213-003-1582-z. View

15.

Fukuyama K, Fukuzawa M, Shiroyama T, Okada M . Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant α4 subunit of nicotinic ACh receptor. Br J Pharmacol. 2020; 177(9):2143-2162. PMC: 7161548. DOI: 10.1111/bph.14974. View

16.

Li Q, Li Q, Jia J, Liu Z, Zhou H, Mao X . Targeting gap junction in epilepsy: Perspectives and challenges. Biomed Pharmacother. 2018; 109:57-65. DOI: 10.1016/j.biopha.2018.10.068. View

17.

Sutton L, Honardoust D, Mouyal J, Rajakumar N, Rushlow W . Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J Neurochem. 2007; 102(1):153-69. DOI: 10.1111/j.1471-4159.2007.04527.x. View

18.

Zheng W, Xiang Y, Yang X, Xiang Y, De Leon J . Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2017; 78(5):e498-e505. DOI: 10.4088/JCP.16r10782. View

19.

Yoshida S, Okada M, Zhu G, Kaneko S . Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology. 2007; 52(7):1538-46. DOI: 10.1016/j.neuropharm.2007.02.009. View

20.

Ronaldson K, Fitzgerald P, Taylor A, Topliss D, Wolfe R, McNeil J . Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012; 141(2-3):173-8. DOI: 10.1016/j.schres.2012.08.018. View